# Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma

> **NCT00355862** · PHASE3 · COMPLETED · sponsor: **University of Regensburg** · enrollment: 525 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT00355862
- **Lead sponsor:** University of Regensburg
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2009-04
- **Final completion:** 2014-05
- **Target enrollment:** 525 (ACTUAL)
- **Last updated:** 2014-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00355862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00355862, "Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00355862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*